Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR

[1]  I. Bièche,et al.  Molecular Profiles of Neurofibromatosis Type 1-Associated Plexiform Neurofibromas , 2004, Clinical Cancer Research.

[2]  Olivier Cussenot,et al.  Gene expression profiling in clinically localized prostate cancer: a four-gene expression model predicts clinical behavior. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  M. Pierotti,et al.  p15INK4b, p14ARF, and p16INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  G. Clark,et al.  RASSF2 Is a Novel K-Ras-specific Effector and Potential Tumor Suppressor* , 2003, Journal of Biological Chemistry.

[5]  J. Keats,et al.  RHAMM is a centrosomal protein that interacts with dynein and maintains spindle pole stability. , 2003, Molecular biology of the cell.

[6]  V. Paradis,et al.  A quantitative gene expression study suggests a role for angiopoietins in focal nodular hyperplasia. , 2003, Gastroenterology.

[7]  J. Minna,et al.  NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers , 2003, Oncogene.

[8]  D. Gutmann,et al.  Neurofibromatosis 1: closing the GAP between mice and men. , 2003, Current opinion in genetics & development.

[9]  R. Reddel,et al.  Telomere maintenance and cancer ? look, no telomerase , 2002, Nature Reviews Cancer.

[10]  Aubrey E. Hill,et al.  Comparative gene expression profile analysis of GLI and c-MYC in an epithelial model of malignant transformation. , 2002, Cancer research.

[11]  M. Teh,et al.  FOXM1 is a downstream target of Gli1 in basal cell carcinomas. , 2002, Cancer research.

[12]  G. Melino,et al.  p73: Friend or foe in tumorigenesis , 2002, Nature Reviews Cancer.

[13]  Arie Perry,et al.  Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays. , 2002, The American journal of pathology.

[14]  D. Burns,et al.  Neurofibromas in NF1: Schwann Cell Origin and Role of Tumor Environment , 2002, Science.

[15]  H. Iwasaki,et al.  Frequent genomic imbalances in chromosomes 17, 19, and 22q in peripheral nerve sheath tumours detected by comparative genomic hybridization analysis , 2002, The Journal of pathology.

[16]  P. Sánchez,et al.  Gli and hedgehog in cancer: tumours, embryos and stem cells , 2002, Nature Reviews Cancer.

[17]  I. Goldberg,et al.  Complex roles of tissue inhibitors of metalloproteinases in cancer , 2002, Oncogene.

[18]  H. Taubert,et al.  Co-expression of survivin and TERT and risk of tumour-related death in patients with soft-tissue sarcoma , 2002, The Lancet.

[19]  D. Gutmann,et al.  International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. , 2002, Cancer research.

[20]  M. Nóbrega,et al.  Gene Expression Profiling Leads to Identification of GLI1-binding Elements in Target Genes and a Role for Multiple Downstream Pathways in GLI1-induced Cell Transformation* , 2002, The Journal of Biological Chemistry.

[21]  K. Leroy,et al.  Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1: a clinicopathologic and molecular study of 17 patients. , 2001, Archives of dermatology.

[22]  T. Jacks,et al.  NF1 Tumor Suppressor Gene Function Narrowing the GAP , 2001, Cell.

[23]  I. Bièche,et al.  Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy. , 2001, Cancer research.

[24]  I. Stamenkovic.  Matrix metalloproteinases in tumor invasion and metastasis. , 2000, Seminars in cancer biology.

[25]  P. Iannaccone,et al.  The sonic hedgehog-patched-gli pathway in human development and disease. , 2000, American journal of human genetics.

[26]  C. Birchmeier,et al.  Neuregulin, a factor with many functions in the life of a Schwann cell , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[27]  Andreas Zimmer,et al.  Patched Target Igf2 Is Indispensable for the Formation of Medulloblastoma and Rhabdomyosarcoma* , 2000, The Journal of Biological Chemistry.

[28]  Chun Xing Li,et al.  Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3 , 2000, Nature Genetics.

[29]  G. Benvenuto,et al.  Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. , 2000, The Journal of clinical investigation.

[30]  Karlyne M. Reilly,et al.  Mouse models of tumor development in neurofibromatosis type 1. , 1999, Science.

[31]  B. Scheithauer,et al.  Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas. , 1999, The American journal of pathology.

[32]  C. Cordon-Cardo,et al.  Expression of p27(kip) and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas: the emerging role of p27(kip) in malignant transformation of neurofibromas. , 1999, The American journal of pathology.

[33]  D. Louis,et al.  Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. , 1999, The American journal of pathology.

[34]  B. Scheithauer,et al.  Tumors of the peripheral nervous system , 1999 .

[35]  I. Bièche,et al.  Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. , 1999, Clinical chemistry.

[36]  J. Morgan,et al.  Physical mapping of the CXC chemokine locus on human chromosome 4 , 1999, Cytogenetic and Genome Research.

[37]  J. Woodruff.  Pathology of tumors of the peripheral nerve sheath in type 1 neurofibromatosis. , 1999, American journal of medical genetics.

[38]  J. Friedman.  Epidemiology of neurofibromatosis type 1. , 1999, American journal of medical genetics.

[39]  Stefanie Turley,et al.  The Hyaluronan Receptor RHAMM Regulates Extracellular-regulated Kinase* , 1998, The Journal of Biological Chemistry.

[40]  W. Reik,et al.  Imprinting of IGF2 and H19: lack of reciprocity in sporadic Beckwith-Wiedemann syndrome. , 1997, Human molecular genetics.

[41]  M. Nakafuku,et al.  A binding site for Gli proteins is essential for HNF-3beta floor plate enhancer activity in transgenics and can respond to Shh in vitro. , 1997, Development.

[42]  L. Kindblom,et al.  Immunohistochemical and molecular analysis of p53, MDM2, proliferating cell nuclear antigen and Ki67 in benign and malignant peripheral nerve sheath tumours , 1995, Virchows Archiv.

[43]  R. Basu,et al.  Cloning and characterization of the human neutrophil-activating peptide (ENA-78) gene. , 1994, The Journal of biological chemistry.

[44]  P. Marynen,et al.  TP53 mutations are frequent in malignant NFI tumors , 1994, Genes, chromosomes & cancer.

[45]  V. Quaranta,et al.  Beta 4 integrin expression in myelinating Schwann cells is polarized, developmentally regulated and axonally dependent. , 1994, Development.

[46]  D. Lowy,et al.  Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis , 1992, Cell.

[47]  B. Brownstein,et al.  Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. , 1990, Science.

[48]  P. O'Connell,et al.  A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations , 1990, Cell.

[49]  Jeng-Shin Lee,et al.  Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[50]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[51]  Harlan I. Firminger,et al.  Atlas of tumor pathology , 1954 .

[52]  A. Stout,et al.  Tumors of the peripheral nervous system. , 1970, Human pathology.

[53]  H. B. Mann,et al.  On a Test of Whether one of Two Random Variables is Stochastically Larger than the Other , 1947 .

[54]  D. Altieri.  Validating survivin as a cancer therapeutic target , 2003, Nature Reviews Cancer.

[55]  Ronald W. Davis,et al.  Transcriptional regulation and function during the human cell cycle , 2001, Nature Genetics.

[56]  K. Nave,et al.  The transcription factor Sox10 is a key regulator of peripheral glial development. , 2001, Genes & development.

[57]  P. Black,et al.  Parathyroid Hormone-Related Protein and its Receptor in Human Glial Tumors , 2000, Acta Neurochirurgica.

[58]  D. Kolson,et al.  Chemokines and peripheral nerve demyelination. , 1999, Journal of neurovirology.

[59]  L. Penland,et al.  Use of a cDNA microarray to analyse gene expression patterns in human cancer , 1996, Nature Genetics.

[60]  J. Kuratsu,et al.  Expression of osteopontin in human glioma. Its correlation with the malignancy. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[61]  F. Collins,et al.  Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis , 1993, Nature Genetics.

[62]  R. Reed,et al.  Tumors of the peripheral nervous system , 2022 .